Enthera Pharmaceuticals
Business Services · Italy · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Via Gioberti 8, Milano, Lombardy, 20123,...Phone Number
+39 23456778Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Enthera Pharmaceuticals
Enthera Srl, founded in 2016 and headquartered in Lombardy, Italy, is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enthera Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Enthera Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Enthera Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Enthera Pharmaceuticals
Website visits: Recent activity has been detected on your website
Click to see if Enthera Pharmaceuticals had a recent Job posting/layoffs
Enthera Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Enthera Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Enthera Pharmaceuticals has new funding data
Product Launch: Get notified when Enthera Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Enthera Pharmaceuticals
Find more new buyers
Company Profile Activity
Activity Insights
Enthera Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Enthera Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Enthera Pharmaceuticals.
Enthera Pharmaceuticals financials insights
Gather financial insights about Enthera Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$42.4M
Enthera Pharmaceuticals Tech Stack
A closer look at the technologies used by Enthera Pharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Funding
Funding
Enthera Pharmaceuticals News & Media
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein (IGFBP) family for selected inflammatory diseases, today announced the appointment of Lisa M. Olson, Ph.D., as the company’s Chief Executive Officer. Dr. Olson joins Enthera’s management team with over two decades of leadership experience in the biopharmaceutical industry including a successful career atEnthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001. Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Elevated levels of IGFBP3 bind to the TMEM219 receptor, causing apoptEnthera Pharmaceuticals Appoints Filippo Canducci as Chief Medical Officer
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer. Dr. Canducci brings more than 20 years of experience in translational medicine, clinical research and drug development in inflammatory and autoimmune diseases. Prior to joining Enthera, Dr. Canducci was a senior medical leader at Roche where he led global teamsEnthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the final closing of its Series A financing, with a total financing of €35m. The Roche Venture Fund joins a renowned international investment syndicate following the fundraising’s first close of €28m which was announced in Ju
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enthera Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Enthera Srl, founded in 2016 and headquartered in Lombardy, Italy, is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowe... Read More
